Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1494-5000

  Sakoulas, George ^a   Rose, Warren ^b   Nonejuie, Poochit ^a   Olson, Joshua ^a   Pogliano, Joseph ^a   Humphries, Romney ^c   Nizet, Victor ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFTAROLINE; CEFTRIAXONE; DAPTOMYCIN; POLYLYSINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL SURFACE; COLONY FORMING UNIT; GROWTH RATE; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE FLUIDITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SURFACE CHARGE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECIUM;

ANTI-BACTERIAL AGENTS; CELL WALL; CEPHALOSPORINS; DAPTOMYCIN; DRUG SYNERGISM; ENTEROCOCCUS FAECIUM; MEMBRANE FLUIDITY; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN RESISTANCE;

EID: 84896867461     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02274-13     Document Type: Article

References (25)

1. Kelesidis T, Humphries Uslan DZ, Pegues DA. 2011. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin. Infect. Dis. 52:228-234. http://dx.doi.org/10.1093/cid/ciq113.
2. Orloff SL, Busch AM, Olyaei AJ, Corless CL, Benner KG, Flora KD, Rosen HR, Rabkin JM. 1999. Vancomycin-resistant Enterococcus in liver transplant patients. Am. J. Surg. 177:418-422. http://dx.doi.org/10.1016/S0002-9610(99) 00083-5. (Pubitemid 29252814)
3. Kamboj M, Chung D, Seo SK, Pamer EG, Sepkowitz KA, Jakubowski AA, Papanicolaou G. 2010. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol. Blood Marrow Transplant. 16:1576-1581. http://dx.doi.org/10.1016/j.bbmt.2010.05.008.
4. Arias CA, Contreras GA, Murray BE. 2010. Management of multidrug-resistant enterococcal infections. Clin. Microbiol. Infect. 16:555-562. http://dx.doi.org/10.1111/j.1469-0691.2010.03214.x.
5. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. 2012. Ampicillin enhances daptomycin- and cationic host defense peptide-mediate killing of ampicillin and vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56: 838-844. http://dx.doi.org/10.1128/AAC.05551-11.
6. Humphries RM, Kelesidis T, Tewhey R, Rose WE, Schork N, Nizet N, Sakoulas. G. 2012. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin non-susceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56:6051-6053. http://dx.doi.org/10.1128/ AAC.01318-12.
7. Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MM, Sheth A, Carpenter CF, Rybak MJ. 2008. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 52:831-836. http://dx.doi.org/10.1128/AAC.00869-07. (Pubitemid 351358359)
8. CLSI. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Forest Laboratories Inc. 10 October 2012, accession date. Ceftaroline fosamil package insert. Forest Laboratories Inc., New York, NY. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/200327s000lbl.pdf.
10. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323. http://dx.doi.org/10.1128/AAC.47.4.1318-1323.2003. (Pubitemid 36368592)
11. Foulds G. 1983. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev. Infect. Dis. 8(Suppl 5):S503-S511.
12. Patel IH, Chen S, Parsonnet Hackman MR, Brooks MA, Konikoff J, Kaplan SA. 1981. Pharmacokinetics of ceftriaxone in humans. Antimicrob. Agents Chemother. 20:634-641. http://dx.doi.org/10.1128/AAC.20.5.634. (Pubitemid 12168041)
13. Dryden MS. 2011. Linezold pharmacokinetics and pharmacodynamics in clinical treatment. J. Antimicrob. Chemother. 66(Suppl 4):iv7-iv15.
14. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillinresistant Staphylococcus aureus: role of daptomycin binding. Clin. Infect. Dis. 53:158-163. http://dx.doi.org/10.1093/cid/cir340.
15. Rice LB, Carias LL, Rudin S, Hutton R, Marshall S, Hassan M, Josseaume N, Dubost L, Marie A, Arthur M. 2009. Role of class A penicillin-binding proteins in the expression of beta-lactam resistance in Enterococcus faecium. J. Bacteriol. 191:3649. http://dx.doi.org/10.1128/JB.01834-08.
16. Zhang X, Paganelli FL, Bierschenk D, Kuiper A, Bonten MJM, Willems RJL, van Schaik W. 2012. Genome-wide identification of ampicillin resistance determinants in Enterococcus faecium . PLoS Genet. 8 (6): e1002804. http://dx.doi.org/10.1371/journal.pgen.1002804.
17. Kawada-Matsuo M, Yoshida Y, Nakamura N, Konatsuzawa H. 2011. Role of two-component systems in the resistance of Staphylococcus aureus to antibacterial agents. Virulence 2:427-430. http://dx.doi.org/10.4161/viru.2.5. 17711.
18. Sakoulas G, Okumura CY, Thienphrapa, Olson J, Nonejuie P, Dam Q, Dhand A, Pogliano J, Yeaman MR, Hensler ME, Bayer AS, Nizet V. 3 December 2013. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J. Mol. Med. http://dx.doi.org/10.1007/s00109-013-1100-7.
19. Berti A, Sakoulas G, Nizet V, Tewhey R, Rose WE. 2013. β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 57:5005-5012. http://dx.doi.org/10.1128/AAC.00594-13.
20. Mishra NN, Bayer AS, Tran TT, Shamoo Y, Mileykovskaya E, Dowhan W, Guan Z, Arias CA. 2012. Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content. PLoS One 7(8):e43958. http://dx.doi.org/10.1371/journal.pone.0043958.
21. Munita JM, Panesso D, Diaz L, Tran TT, Reyes J, Wanger A, Murray BE, Arias CA. 2012. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob. Agents Chemother. 56:4354-4359. http://dx.doi.org/10.1128/AAC.00509-12.
22. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM, Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE, Weinstock GM. 2011. Genetic basis for in vivo daptomycin resistance in enterococci. N. Engl. J. Med. 365:892-900. http://dx.doi.org/10.1056/NEJMoa1011138.
23. Xavier H, Amoroso A, Coyette J, Joris B. 2010. Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium. Antimicrob. Agents Chemother. 54:953-955. http://dx.doi.org/10.1128/AAC.00983-09.
24. Sakoulas G, Noneluie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F. 2013. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob. Agents Chemother. 57:4042-4045. http://dx.doi.org/10.1128/AAC.02481-12.
25. King EA, McCoy D, Desai S, Nyirenda T, Bicking K. 2011. Vancomycin-resistant Enterococcal bacteremia and daptomycin: are higher doses necessary? J. Antimicrob. Chemother. 66:2112-2118. http://dx.doi.org/10.1093/ jac/dkr255.